Please assess the completion status of the following clinical trial:

Trial Title: OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years old~2. Patients with STEMI (onset of pain\<12 hours) with indication for primary PCI~3. Informed consent obtained in writing~Exclusion Criteria:~Pregnancy/Breastfeeding~* Severe nausea or vomiting~* Treatment with a P2Y12 inhibitor within the previous 1 month~* Inability to give informed consent~* Hemodynamic instability~* Arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents~* Killip class ≥3~* Known hypersensitivity to ticagrelor~* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.~* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding~* Thombocytopenia (\<100.000 / μL) at randomization~* Anaemia (Hct \<30%) at randomization~* Polycytaemia (Hct \> 52%) at randomization~* Periprocedural IIb/IIIa inhibitor administration~* Thrombolysis administration~* Recent (\< 6 weeks) major surgery or trauma, including GABG.~* Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).~* Patients considered by the investigator to be at increased risk of bradycardiac events.~* Dialysis required.~* Severe uncontrolled chronic obstructive pulmonary disease~* Known severe hepatic impairement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 180mg whole tablets (Type: ACTIVE_COMPARATOR): Ticagrelor 180mg loading dose, in the form of 2 whole tablets administered per os in the supine position (standard administration)
- Ticagrelor 180mg crushed and dispersed (Type: EXPERIMENTAL): Ticagrelor 180mg in the form of 2 tablets crushed and dispersed in purified water administered per os with 1-minute-stay in a 60-70 degrees semi-upright sitting position

Based on this trial design, predict the completion outcome and termination type (if applicable).